A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients.
about
Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone RemodelingDual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkersThe effects of proteasome inhibitors on bone remodeling in multiple myeloma.The best of both worlds - managing the cancer, saving the bone.Bone anabolic agents for the treatment of multiple myeloma.Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growthImpaired osteoblastogenesis in a murine model of dominant osteogenesis imperfecta: a new target for osteogenesis imperfecta pharmacological therapy.Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitors.The effects of bortezomib on bone disease in patients with multiple myeloma.Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma.The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors.Emerging treatment approaches for myeloma-related bone disease.West Nile virus and dengue virus capsid protein negates the antiviral activity of human Sec3 protein through the proteasome pathway.The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling.Bone healing in multiple myeloma: a prospective evaluation of the impact of first-line anti-myeloma treatment.Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients.VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT.The Proteasome and Myeloma-Associated Bone Disease.Thymic PTH Increases after Thyroparathyroidectomy in C57BL6/KaLwRij Mice.High-dose therapy improves the bone remodelling compartment canopy coverage and bone formation in multiple myeloma.Myeloma bone disease: Pathophysiology and management.Surgical thyroparathyroidectomy prevents progression of 5TGM1 murine multiple myeloma in vivo.The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: Final results on 205 patients of the Greek myeloma study groupFewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma
P2860
Q28082335-3FC8DD07-235F-4503-B4B5-F2EA931C7422Q33415397-498CA717-CE16-4D10-B259-79395D220C17Q33918020-1466802D-D592-4015-82EC-2D06BCB90CA0Q33920055-64EC9AB9-9CF0-438C-AC55-4E87131D5558Q35603116-DC6C446F-CF87-4AAF-B09A-84F99907BED1Q36092153-1A303878-523F-4CB1-B4DB-3F589BA44510Q36282399-712346EB-5B4D-44BC-B4C3-BE8A6A910710Q37668104-18AEC835-B2ED-44D8-B0F0-50B2DDF7B5BAQ38163937-10AC5FB2-F146-4B8A-B48C-07B9B23868C1Q38752859-C80D1B61-6BB3-4BD7-AAFA-6769252DCE04Q38820789-3569EB2B-936E-478D-9247-E46FB2476307Q39090721-FAFD3472-B438-4E99-8CBE-3050CE052371Q39177065-377127E8-2088-46E8-8D20-7F6520A4B19DQ39212192-B7ED9B9E-73CF-40C2-9283-89034DB922DAQ42388534-AA3FF38D-D21B-49CB-9E68-DC5A884CF900Q43409328-80A47F92-E4BE-4540-BDC7-595D056E7294Q43759174-E3559E53-5A3B-42B4-9DAE-3E7B662DA088Q47696279-70E2DA8E-F580-4637-973D-B90741E2E838Q49577729-0E871D20-24A1-453B-8AE0-9049F6D8D0F9Q53407176-893007F8-49F2-482D-B12C-BD22E82D44A7Q55209965-7D105C9F-4A12-4088-91ED-4D8449E2056DQ55265829-C50AD66E-3E4E-4E96-ADCD-A24D52DE2B79Q57904348-7A43E782-87B0-411E-BBD4-8EEB8BBBF9BEQ57904558-A08EDE0B-12BF-4E4B-B65C-67505683D90D
P2860
A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A prospective evaluation of th ...... in multiple myeloma patients.
@ast
A prospective evaluation of th ...... in multiple myeloma patients.
@en
A prospective evaluation of th ...... in multiple myeloma patients.
@nl
type
label
A prospective evaluation of th ...... in multiple myeloma patients.
@ast
A prospective evaluation of th ...... in multiple myeloma patients.
@en
A prospective evaluation of th ...... in multiple myeloma patients.
@nl
prefLabel
A prospective evaluation of th ...... in multiple myeloma patients.
@ast
A prospective evaluation of th ...... in multiple myeloma patients.
@en
A prospective evaluation of th ...... in multiple myeloma patients.
@nl
P2093
P2860
P1433
P1476
A prospective evaluation of th ...... in multiple myeloma patients.
@en
P2093
Dixie Esseltine
Federica Cavallo
Fenghuang Zhan
Guido Tricot
J Michael Gruenwald
Larry J Suva
Lisa Pappas
Naveen Sanath Kumar
Steven Kern
Subramanian Ranganathan
P2860
P304
P356
10.3324/HAEMATOL.2010.031302
P577
2010-10-15T00:00:00Z